Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.07 USD
Change Today -0.08 / -1.55%
Volume 80.6K
ECYT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 11:31 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

endocyte inc (ECYT) Snapshot

Open
$5.09
Previous Close
$5.15
Day High
$5.17
Day Low
$5.05
52 Week High
09/10/14 - $9.35
52 Week Low
08/24/15 - $4.61
Market Cap
212.8M
Average Volume 10 Days
359.0K
EPS TTM
$-0.83
Shares Outstanding
42.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDOCYTE INC (ECYT)

endocyte inc (ECYT) Related Businessweek News

No Related Businessweek News Found

endocyte inc (ECYT) Details

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial in recurrent prostate cancer patients. The company is also developing EC1788, a folate receptor-targeted SMDC that is in preclinical development stage to treat cancer; EC1669, which is in preclinical development stage to treat inflammatory diseases; and EC0371 that is in preclinical development stage for the treatment of polycystic kidney disease. In addition, it develops Etarfolatide, a companion imaging agent for its SMDCs that target folate receptor; and EC0652, a diagnostic imaging agent targeting prostate-specific membrane antigen. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of Vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.

81 Employees
Last Reported Date: 03/13/15
Founded in 1995

endocyte inc (ECYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $475.6K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $208.7K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $323.0K
Vice President of Research & Development
Total Annual Compensation: $278.5K
Vice President of Clinical Operations
Total Annual Compensation: $261.8K
Compensation as of Fiscal Year 2014.

endocyte inc (ECYT) Key Developments

Endocyte, Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015; Reiterates Cash Guidance for 2015; Provides Update on Clinical Progress

Endocyte, Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. For the quarter, collaboration revenue was $0.013 million against $49.168 million a year ago. Loss from operations was $10.782 million against income from operation of $22.210 million a year ago. Interest income, net was $0.185 million against $0.168 million a year ago. Net loss was $10.604 million or $0.25 per diluted share against net income of $22.356 million or $0.52 per diluted share a year ago. Research and development expenses were $6.7 million for the second quarter of 2015, compared to $19.0 million for the same period in 2014. Research and development expenses were $6.7 million for the second quarter of 2015, compared to $19.0 million for the same period in 2014. The decrease in research and development expense was primarily attributable to a decrease in expenses related to the TARGET trial, which is now completed, and the PROCEED trial, which was terminated in May 2014 and for which a termination charge of $4.7 million was recorded in the second quarter of 2014, along with a decrease in manufacturing expenses for vintafolide and etarfolatide related to pre-commercial activity. For the six months, collaboration revenue was $0.025 million against $66.437 million a year ago. Loss from operations was $21.747 million against income from operation of $18.991 million a year ago. Interest income, net was $0.337 million against $0.253 million a year ago. Net loss was $21.474 million or $0.47 per diluted share against net income of $19.215 million or $0.51 per diluted share a year ago. The company reiterated its expectation that its 2015 year-end cash balance will exceed $155 million. Spending is expected to increase from current levels as the trials for EC1456 and EC1169 are expanded once the maximum tolerated doses are determined. The company also announced that the final overall survival results from the Phase 2 TARGET trial of EC145 in NSCLC have been accepted for oral presentation at the IASLC World Conference on Lung Cancer to be held in Denver from September 6-9, 2015. While development efforts have focused on the second generation SMDCs, results of this trial provide insights into the effectiveness of the SMDC platform, particularly in targeting the folate receptor.

Endocyte, Inc. Appoints Dr. Alison A. Armour as Chief Medical Officer

Endocyte, Inc. announced that Alison A. Armour has been appointed as chief medical officer. Prior to joining Endocyte, Dr. Armour served as vice president of oncology at Novartis and GSK, where she led the global strategic TYKERB development team in breast cancer and was accountable for a large matrix team composed of clinical, medical, regulatory, statistics, medical affairs, science and commercial colleagues based in multiple sites in the US, UK and Japan.

Endocyte, Inc., Q2 2015 Earnings Call, Aug 04, 2015

Endocyte, Inc., Q2 2015 Earnings Call, Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECYT:US $5.07 USD -0.08

ECYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ECYT.
View Industry Companies
 

Industry Analysis

ECYT

Industry Average

Valuation ECYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 56.4x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOCYTE INC, please visit www.endocyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.